clinical trial · NCT03378531
A Study of AEB1102 (Pegzilarginase) in Patients With Arginase 1 Deficiency
Arginase I DeficiencyHyperargininemiaAEB1102
brief summary
The purpose of this study is to determine the safety, tolerability, and efficacy of long-term intravenous and subcutaneous administration of pegzilarginase for the treatment of pediatric and adult patients with ARG1-D who complete Study CAEB1102-101A.
started
Dec 7, 2017
primary completion
Dec 15, 2022
completion
Dec 15, 2022
last updated
Sep 24, 2026
detailed description
Purpose of this study is to determine the safety, tolerability, and efficacy of long-term intravenous and subcutaneous administration of pegzilarginase for the treatment of pediatric and adult patients with ARG1-D who complete Study CAEB1102-101A.
official title
An Open-label, Multicentre Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of AEB1102 in Patients With Arginase 1 Deficiency
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol